BIO Early-Stage Resources Hub

Access a range of exclusive resources, including cost-saving programs, educational webinars and stay up-to-date with the latest BIO Emerging Companies Section (ECS) events with our comprehensive resource center, designed to empower early-stage companies and help them thrive.

  • Show All
Results
  • Show All
PDF
BIO Issue Brief: Committee on Foreign Investment in the United States (CFIUS) (9/22/2022)
FLIP
An overview of CFIUS and how the Administration’s focus on protecting the U.S. Biotech Industry could cause unintentional harm by impeding foreign investment and collaborations.
FLIP
PDF
BIO Letter of Support: Short Sale Transparency and Market Fairness Act (7/29/2021)
FLIP
BIO Support of H.R. 4618, to amend short sale reporting requirements.
FLIP
PDF
BIO Letter to Senate Banking Cmte: Proposals to Foster Capital Formation and Economic Growth in the Bioeconomy (3/18/2021)
FLIP
BIO Letter to Senate Banking Committee in support of proposals to foster capital formation for biotechs.
FLIP
PDF
Cybersecurity Risk Management, Strategy, Governance, and Incident Disclosure (5/5/2022)
FLIP
Comments on proposed rule to enhance and standardize disclosures regarding cybersecurity risk management, strategy, governance, and incident reporting by public companies.
FLIP
PDF
FTC Comment Letter: Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers (5/5/2022)
FLIP
Comments in response to FTC Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers.
FLIP
PDF
FTC Comment Letter: Request for Comment on Pharmaceutical Task Force, Project No. P212900 (6/13/2021)
FLIP
Comments in response to Federal Trade Commission’s Pharmaceutical Task Force’s request for public comment.
FLIP
PDF
FTC Comment Letter: Request for Information on Merger Enforcement (4/15/2022)
FLIP
Comments to FTC on merger enforcement.
FLIP
PDF
Minimum Pricing Increments, Access Fees, and Transparency of Better Priced Orders (3/30/2023)
FLIP
Comments on proposed rule to adapt a variable minimum pricing increments for the quoting and trading of NMS stocks, reduce access fee caps, and enhance transparency of better priced orders.
FLIP
PDF
Request for Comment on Proposed Amendments to Rules Governing Proxy Voting Advice (12/23/2021)
FLIP
Comments on proposed rule governing proxy voting advice.
FLIP
PDF
SEC Comment Letter: Order Competition Rule (3/30/2023)
FLIP
Comments on proposed rule to amend regulations governing the national market system (NMS).
FLIP
PDF
SEC Comment Letter: Request for Comment on Climate Risk Disclosures (6/13/2021)
FLIP
Comments on SEC request for information on climate risk disclosures.
FLIP
PDF
SEC Comment Letter: Short Position and Short Activity Reporting (4/25/2022)
FLIP
Comments on proposed rule to require money managers to disclose within 14 calendar days after month-end certain gross short positions on companies.
FLIP
PDF
Statement for the Record: "A Roadmap for Growth: Reforms to Encourage Capital Formation and Investment Opportunities for All Americans" (4/23/2023)
FLIP
Statement for the Record to House Financial Services Committee, Subcommittee on Capital Markets.
FLIP
PDF
Testimony: "The Impact of Consolidation and Monopoly Power on American Innovation" (12/15/2021)
FLIP
Testimony of BIO’s Chief Policy Officer before the Senate Subcommittee on Competition Policy, Antitrust, and Consumer Rights on consolidation and monopoly power.
FLIP
FILE
The Enhancement and Standardization of Climate-Related Disclosures for Investors (6/17/2022)
FLIP
Comments on proposed rule to require information about a registrant’s climate-related risks that are reasonably likely to have a material impact on its business, results of operations, or financial condition.
FLIP